国际医药卫生导报2012，Vol.18Issue(14)：2040-2042,3.DOI:10.3760/cma.j.issn.1007-1245.2012.14.022
培美曲赛联合方案一线治疗ⅢB/Ⅳ期肺腺癌的临床观察
Clinical observation on pemetrexed combination regimen as first-line treatment for ⅢB/Ⅳ lung adenocarcinoma
瞿燕春 1曲鑫 1李勇 1白建平 1刘译鸿 1刘丽荣 1张海波1
作者信息
摘要
Abstract
[Objective]To observe the clinical efficacy and toxicities of pemetrexed combined with platinum as the first-line regimen for ⅢB/Ⅳ lung adenocarcinoma.[Methods]20 patients with ⅢB/Ⅳ lung adenocarcinoma received pemetrexed combined with platinum chemotherapy as the first-line treatment,the clinical efficacy and toxicities were evaluated after at least 2 cycles of chemotherapy.[Results]Among all 20 cases,no case with CR,5 cases with PR,12 cases with SD,3 cases with PD were found,the total effective rate was 25％ and the total disease control rate was 85％.The main toxicities were hone marrow depression and gastrointestinal reaction.[Conclusion]The pemetrexed combined with platinum as the first-line regimen in the treatment for ⅢB/Ⅳ lung adenocarcinoma has reliable efficacy and less toxicities.关键词
肺腺癌/培美曲赛/一线治疗Key words
Lung adenocarcinoma/Pemetrexed/First-line treatment引用本文复制引用
瞿燕春,曲鑫,李勇,白建平,刘译鸿,刘丽荣,张海波..培美曲赛联合方案一线治疗ⅢB/Ⅳ期肺腺癌的临床观察[J].国际医药卫生导报,2012,18(14):2040-2042,3.
